Gene · 5336
Papers3,625
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,625
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy. | Leuk Lymphoma | 2025 | 39972943 | PubTator, text mining | PubMed |
| Identification of Potential Diagnostic Biomarkers of Carotid Atherosclerosis in Obese Populations. | J Inflamm Res | 2025 | 39959637 | PubTator, text mining | PubMed |
| Tissue nanotransfection-based endothelial PLCγ2-targeted epigenetic gene editing rescues perfusion and diabetic ischemic wound healing. | Mol Ther | 2025 | 39863930 | PubTator, text mining | PubMed |
| Overexpression of PLCG2 and TMEM38A inhibit tumor progression in clear cell renal cell carcinoma. | Sci Rep | 2025 | 39863641 | PubTator, text mining | PubMed |
| Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. | Blood Adv | 2025 | 39853273 | PubTator, text mining | PubMed |
| Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors. | Ann Hematol | 2025 | 39849159 | PubTator, text mining | PubMed |
| Monoallelic expression can govern penetrance of inborn errors of immunity. | Nature | 2025 | 39743591 | PubTator, text mining | PubMed |
| Splice site and de novo variants can cause PLCG2-associated immune dysregulation with cold urticaria. | J Allergy Clin Immunol | 2025 | 39667583 | PubTator, text mining | PubMed |
| Prevalence of BTK and PLCG2 Mutations in CLL Patients With Disease Progression on BTK Inhibitor Therapy: A Meta-Analysis. | Am J Hematol | 2025 | 39643600 | PubTator, text mining | PubMed |
| Isorhynchophylline Inhibits Platelet Activation and Thrombus Formation. | J Cardiovasc Pharmacol | 2025 | 39620592 | PubTator, text mining | PubMed |
| An unusual oral manifestation of chronic lymphocytic leukemia: A case report and review of the literature. | J Am Dent Assoc | 2025 | 39601734 | PubTator, text mining | PubMed |
| A novel role for thioredoxin-related transmembrane protein TMX4 in platelet activation and thrombus formation. | J Thromb Haemost | 2025 | 39307246 | PubTator, text mining | PubMed |
| PLCG2, A Regulator of Lung Adenocarcinoma Proliferation and Migration Associated with Immune Infiltration. | Curr Cancer Drug Targets | 2025 | 39177130 | PubTator, text mining | PubMed |
| Angiopoietin-like protein 2 inhibits thrombus formation. | Mol Cell Biochem | 2025 | 38880861 | PubTator, text mining | PubMed |
| Multi-phased Kinetics and Interaction of Protein Kinase Signaling in Glycoprotein VI-Induced Platelet αIIbβ3 Integrin Activation and Degranulation. | Thromb Haemost | 2025 | 38653482 | PubTator, text mining | PubMed |
| The PLCG2 Inhibits Tumor Progression and Mediates Angiogenesis by VEGF Signaling Pathway in Clear Cell Renal Cell Carcinoma. | Front Biosci (Landmark Ed) | 2024 | 39614428 | PubTator, text mining | PubMed |
| The crystal and cryo-EM structures of PLCγ2 reveal dynamic interdomain recognitions in autoinhibition. | Sci Adv | 2024 | 39612343 | PubTator, text mining | PubMed |
| In Silico Analysis of Non-Conventional Oxidative Stress-Related Enzymes and Their Potential Relationship with Carcinogenesis. | Antioxidants (Basel) | 2024 | 39594421 | PubTator, text mining | PubMed |
| Consistent genes associated with structural changes in clinical Alzheimer's disease spectrum. | Front Neurosci | 2024 | 39554844 | PubTator, text mining | PubMed |
| Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer. | Int J Biol Sci | 2024 | 39494327 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5336/papers?page=9